Guardant Health Announces Board and Executive Compensation Changes
Ticker: GH · Form: 8-K · Filed: 2024-07-18T00:00:00.000Z
Sentiment: neutral
Topics: governance, executive-compensation, board-changes
Related Tickers: GH
TL;DR
Guardant Health swapped a board member and tweaked exec pay. Watch for strategy shifts.
AI Summary
Guardant Health, Inc. announced on July 17, 2024, changes in its board of directors and executive compensation arrangements. Specifically, the company reported the departure of a director and the election of a new director, along with updates to compensatory arrangements for certain officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: low — This filing primarily concerns routine corporate governance and executive compensation updates, which typically carry low immediate risk.
Key Players & Entities
- Guardant Health, Inc. (company) — Registrant
- July 17, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 3100 Hanover Street Palo Alto, California 94304 (address) — Principal executive offices
- 855-698-8887 (phone_number) — Registrant's telephone number
FAQ
Who is the new director elected to the board?
The filing indicates the election of a new director but does not name the individual in the provided text.
Which director has departed from the board?
The filing reports the departure of a director but does not specify their name in the provided text.
What specific changes were made to executive compensation arrangements?
The filing states that there were updates to compensatory arrangements for certain officers, but the details of these changes are not provided in the excerpt.
What is the primary reason for this 8-K filing?
This 8-K filing is to report on the departure of a director, the election of a new director, and changes to compensatory arrangements of certain officers.
When was the earliest event reported in this filing?
The earliest event reported in this filing occurred on July 17, 2024.
From the Filing
0001193125-24-181093.txt : 20240718 0001193125-24-181093.hdr.sgml : 20240718 20240718171932 ACCESSION NUMBER: 0001193125-24-181093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240717 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240718 DATE AS OF CHANGE: 20240718 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 241125468 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d771601d8k.htm 8-K 8-K false 0001576280 0001576280 2024-07-17 2024-07-17     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 17, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company  ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On July 17, 2024, the Board of Directors (the “Board”) of Guardant Health, Inc. (the “Company”) increased the number of directors on the Board to nine and appointed Manuel Hidalgo Medina, M.D., Ph.D., as a Class II director of the Company, to be effective as of July 17, 2024. Dr. Hidalgo will serve on the Board for a term expiring at the 2026 Annual Meeting of Stockholders and until his successor is duly electe